Healx – the AI-powered technology company developing the next generation of drug discovery for rare diseases – is taking more than 3,500 square foot of space within Chesterford Park’s multi-occupancy lab building.
Ovid Therapeutics has found a potential buyer for its onetime lead program. A little more than one year after gaboxadol’s value-crushing phase 3 flop, Healx has stepped in to see whether it can write another chapter in the long, failure-strewn history of the neurological disease drug.
Cambridge, UK – 20 October 2021. Healx, the AI-powered, patient-inspired technology company pioneering the next generation of drug discovery, is proud to announce that they have received Investigational New Drug (IND) approval from the US Food and Drug Administration (FDA) for the Phase 2a clinical study of HLX-0201. This is one of several compounds that are being developed by Healx to treat fragile X syndrome in the first stage of a combination therapy trial. The IND approval follows the receipt of Orphan Drug Designations in the EU in 2020, and in the US earlier this year. Together, these approvals represent a significant milestone for the company: validating their AI-driven drug discovery approach and formally marking their evolution into a clinical stage company. The team will begin recruitment for participants in the trial in the coming months.
Cambridge rare disease specialist Healx has struck its latest patient group partnership – with Ataxia UK and FARA, The Friedreich’s Ataxia Research Alliance.
The AI-centric drug discovery technology firm is working with a foundation to discover potential treatments for the rare neurogenetic disorder.
The AI-centric drug discovery technology firm is working with a foundation to discover potential treatments for the rare neurogenetic disorder.
Healx has announced that applications are now being accepted for its Rare Treatment Accelerator (RTA), a new programme focused on finding new treatments for rare diseases by partnering with selected rare disease patient groups.
Healx, the AI-powered and patient-inspired technology company specialising in treatments for rare diseases, today announces that it has raised $56 million in a Series B financing round, led by one of Europe’s largest VC firms Atomico and joined by Intel Capital, Global Brain and btov Partners. All previous investors, including Balderton Capital, Amadeus Capital Partners, and Jonathan Milner also participated in the round. The financing will be used to develop the company’s therapeutic pipeline and to launch its global Rare Treatment Accelerator programme.